

## Special Issue

# Research Advances in Brain Metastasis

### Message from the Guest Editor

The distinct microenvironment in the brain, including the existence of a disrupted blood–brain barrier (BBB), dense cellularity, etc., poses a demanding requirement for clinical diagnosis and treatment of brain metastasis (BM). BM is common in cancer patients, especially in lung cancer, breast cancer and melanoma, and is associated with high mortality. Lack of mandatory screening and reporting may lead to underestimated incidence. Regarding treatment, local treatments such as surgery and radiotherapy (WBRT, SBRT) are only eligible for selected patients, due to the widespread nature of BM and treatment-related complications. The delivery of systemic treatment is hurdled by the BBB, and repurposing of temozolomide in BM has not been validated in large randomized controlled trials. Emerging immune checkpoint inhibitor represents a novel option, yielding long-term response in some cases, and biomarkers to identify eligible patients are under exploration. Hopefully, technically solid and clinically relevant studies on BM may help improve patients' care.

### Guest Editor

Dr. Shuncong Wang

Laboratory of Lipid Metabolism and Cancer, Biomedical Group,  
Campus Gasthuisberg, KU Leuven, 3000 Leuven, Belgium

### Deadline for manuscript submissions

closed (31 December 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/150293](https://mdpi.com/si/150293)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).